Manejo y Tratamiento del Dengue No Grave y el Dengue Grave

Objectives

Provide a national, evidence-based clinical reference for preventing, diagnosing, classifying, treating and controlling dengue across Mexico’s National Health System, covering suspected and confirmed non-severe and severe dengue, including dengue fever and dengue haemorrhagic fever classifications. The guidance forms part of the master catalogue of clinical practice guidelines, implemented through the Clinical Practice Guideline Development Action Programme and aligned with the 2007–2012 National Health Programme.[1][2][3]It seeks to improve the effectiveness, safety and quality of care, reduce variation in clinical practice, support timely referral, reduce dengue incidence and mortality, and lessen dengue’s impact on affected populations.[2][4][3]

• Strengthen primary prevention by controlling Aedes mosquito breeding sites, promoting community education and participation, improving household and peri-domestic environmental management, and supporting reliable potable-water supply and drainage.[5][6]
• Standardise early detection, diagnosis and secondary prevention of non-severe dengue through appropriate clinical assessment, laboratory confirmation where required, hydration, monitoring, patient education and safe outpatient care.[3][7][8]
• Recognise progression to severe dengue through warning signs, plasma leakage, shock, severe bleeding and serious organ involvement, while accounting for comorbidities and social circumstances that may increase risk or hinder outpatient management.[9][10][11][12]
• Ensure timely referral, hospitalisation, intensive care, life support and discharge decisions according to disease severity and the capacity of first-, second- and third-level services.[13][3][14][15]
• Use the revised World Health Organization dengue classification proposed in 2009, distinguishing non-severe dengue with or without warning signs from severe dengue, while retaining earlier classifications for reference and recognising ongoing evaluation of the newer framework.[16][6][9]
• Support epidemiological control through case definitions, laboratory or epidemiological confirmation, notification, surveillance of cases and deaths, and monitoring of vector-breeding risks.[17][6][7][18]

Implementation

Deliver the guidance through Mexico’s three-level National Health System, combining prevention and health promotion at first level with specialist hospital care at second level and highly complex, intensive and specialist services at third level.[2][19][20]Recommendations are intended to inform professional judgement alongside patient needs and preferences, locally available resources, and applicable institutional regulations.[1]Development, validation and review drew on federal and state health authorities, social-security institutions, hospitals, public-health and epidemiology bodies, and multidisciplinary clinical and technical experts.[1][21][22][23]

• Apply an evidence-based development process using adopted or adapted international guidelines, systematic literature review, clinical-question formulation, electronic and manual searches, national contextual analysis, expert input and institutional validation.[21][16]
• Grade evidence and recommendations using the 2008 Scottish Intercollegiate Guidelines Network scale, while using expert consensus where higher-level evidence is unavailable.[16][24][23]
• Manage patients by severity group: provide home care and daily monitoring for stable patients without warning signs, admit and closely observe patients with warning signs or relevant risk factors, and provide urgent stabilisation and hospital referral for critical or severe cases.[25][26][15]
• Assess suspected cases through structured history-taking, physical examination, serial haematocrit and platelet measurements, fluid-balance and urine-output monitoring, and targeted laboratory, imaging, serological or virological tests according to clinical progression and service availability.[27][28][29]
• Notify suspected dengue cases to competent health authorities and use referral and counter-referral procedures between levels of care to support timely, comprehensive and continuous management.[7][18][19]
• Equip referral hospitals with daily full blood counts, haematocrit and platelet testing, imaging for pleural effusion or ascites, serum-sample handling and access to reference laboratories; ensure third-level facilities can provide adult or paediatric intensive care.[26][30]
• Use clinical and laboratory monitoring to guide fluid management, recognising shock and haemorrhage early, reassessing haematocrit and haemodynamic response after fluid interventions, and using blood products selectively when clinically indicated.[31][32][33][34]
• Coordinate governance through the National Centre for Health Technology Excellence, the National Committee for Clinical Practice Guidelines, the Directorate-General for Epidemiology, the National Centre for Epidemiological Surveillance and Disease Control, participating state authorities and other National Health System institutions.[1][3][23][35][36]
• Monitor impact through timely diagnosis and referral, dengue incidence, mortality and case-fatality measures, alongside clinical criteria for deterioration, admission, intensive-care transfer and discharge; however, the source does not specify operational targets, routine reporting schedules, audit procedures or a comprehensive continuing accountability framework.[2][17][37][38]

Monitoring & Evaluation

The guideline combines epidemiological surveillance, diagnostic confirmation, serial clinical monitoring and institutional review to support timely dengue detection, risk stratification, referral and safe discharge. Its high-level intended outcomes are timely diagnosis and referral, lower dengue incidence and mortality, and more consistent clinical care, but it does not establish a unified national performance-management framework with baselines, targets, routine reporting schedules or audit requirements.[2][3][23]

• Use surveillance measures including reported cases, incidence, deaths, case-fatality rates and dengue-virus serotypes, drawing on data from the Directorate-General for Epidemiology, the National Centre for Epidemiological Surveillance and Disease Control, and the National Population Council.[17][39][3]
• Notify suspected dengue cases immediately to the competent health authorities at primary-care level, in accordance with the regionalised care structure.[7]
• Confirm cases through laboratory or epidemiological criteria, including paired-serum immunoglobulin M testing, non-structural protein 1 antigen detection, viral isolation and polymerase chain reaction where applicable.[6][7][12]
• Monitor vector-breeding sites and household risk factors to guide prevention and epidemiological control; reductions in vector density are identified as an outcome of cleaning and educational interventions.[5][6]
• Apply the 2008 Scottish Intercollegiate Guidelines Network evidence-grading scale to present evidence levels and recommendation grades, supported by systematic review, selected guidelines, clinical peer review and institutional validation.[21][16][24]
• Document formal review processes through meetings held from October 2009 to May 2010, with outcomes recorded in minutes and consensus used where higher-level evidence was unavailable.[23]

Clinical monitoring is specified in considerable detail. Assessment covers fever history, fluid and food intake, urine output, warning signs, exposure and travel, comorbidities, social risk, hydration, circulation, respiration, abdominal findings, skin manifestations and bleeding.[27]Serial platelet and haematocrit measurements are central to identifying plasma leakage and progression to the critical phase, particularly when platelet counts fall rapidly as haematocrit rises from the individual baseline.[28]

• Review ambulatory patients daily during the febrile phase and for the first three days after fever resolves, with education for patients and families on warning signs requiring reassessment or referral.[8]
• Monitor Group A patients daily for haematocrit stability, leucopenia, defervescence, warning signs, oral-fluid tolerance and urine output, verifying urine output every six hours.[25]
• Perform daily complete blood and platelet counts in suspected severe dengue until two days after the febrile phase ends, with further biochemical, renal, coagulation, respiratory, imaging, serological and virological tests determined by clinical progression.[29]
• Assess vital signs and peripheral perfusion every one to four hours through the critical phase, measure haematocrit before and after fluid loads and then every six to twelve hours, and monitor glucose, renal and hepatic function and coagulation where indicated.[40]
• Reassess heart rate, pulse, blood pressure, skin colour, temperature, capillary refill, urine output, haematocrit and clinical response throughout fluid resuscitation to prevent inadequate hydration and fluid overload.[32][33]
• Monitor haemodynamic stability, metabolic acidosis, organ function, respiratory status, bleeding, plasma leakage, platelet recovery and haematocrit when deciding on intensive-care admission, transfer and discharge.[30][37]

Referral and discharge criteria provide practical clinical accountability at the point of care, although they are not framed as service-level indicators. Referral decisions should consider warning signs, haemodynamic compromise, bleeding, organ damage, comorbidities, pregnancy, extremes of age, social isolation and barriers to timely outpatient care.[26][29][41]Discharge requires sustained clinical recovery, stable haematocrit without intravenous fluids, improving platelet counts, adequate urine output, absence of respiratory distress and bleeding, resolution of warning signs, restored oral intake and controlled comorbidity.[38]

The guidance identifies institutional responsibilities for clinical-guideline development and review, including the National Centre for Health Technology Excellence, the General Directorate of Epidemiology, the National Centre for Epidemiological Surveillance and Disease Control and participating federal and state health institutions.[1][22][23]However, it does not specify routine facility reporting templates, named accountable officers for implementation results, indicator definitions, data-quality procedures, evaluation intervals, audit cycles or corrective-action processes.[2][3][42]

Costing & Financing

No implementation budget, unit costs, expenditure plan, funding gap, financing proportion, resource-mobilisation strategy or economic assumption is specified. The Federal Secretariat of Health and the state entities of Tamaulipas and Veracruz are identified as funding sources or sponsors, but no monetary contribution or funding period is reported.[2]

• Require clinical resources including full blood counts, platelet and haematocrit testing, laboratory confirmation, imaging for plasma leakage, serum-sample storage and transport, intravenous fluids, essential medicines, blood products and intensive-care capacity for referral services, without monetary values or quantities.[26][30]
• Provide first-, second- and third-level services according to increasing professional specialisation and technological complexity, supported by referral and counter-referral procedures; the extract provides no associated costing.[19][20]
• Support staff participation in evidence-based medicine training and institutional review through state health authorities, but without stated training budgets or resource allocations.[22]

Consequently, the source cannot support assessment of affordability, financial sustainability, cost-effectiveness, unfunded requirements or the adequacy of resources for nationwide implementation.[2][26][22]